PanTera and TerraPower Isotopes join forces to accelerate access to
actinium-225
Strategic collaboration signed to support
the development of radiopharmaceuticals in the
fight against cancer
Chicago, IL, USA, June 26,
2023: TerraPower Isotopes and PanTera, the Belgian joint
venture created by SCK CEN and IBA, announced today that they have
signed a strategic collaboration to increase the global
availability of actinium-225 (225Ac), a radioisotope that has the
potential to treat a large variety of cancer indications. The
companies will work together to increase near-term production of
225Ac1 to support ongoing clinical trials and to ensure the
large-scale supply of the radioisotope in the long term, addressing
growing global demand.
This collaboration will not have any immediate
financial impact but has the potential to bring substantial
revenues in the future to PanTera and, indirectly, to its two
shareholders SCK CEN and IBA, a listed company on the Brussels
stock exchange.
Under this collaboration, both companies will
use TerraPower Isotope’s natural decay method based on thorium-229
(229Th) and PanTera’s “Gamma route” based on the Rhodotron® and
radium-226 to produce 225Ac.
225Ac is a promising alpha emitter for use in
Targeted Alpha Therapy (TAT). A series of molecules that are
currently under research, combined with 225Ac through further
manufacturing, have the potential to treat a variety of cancers,
targeting solid tumors, metastases, and systemic cancers such as
leukemia. There are several clinical studies currently in progress,
ranging from preclinical development through to phase 3 clinical
trials. Whilst there is high demand, there is a scarcity of 225Ac.
The collaboration between PanTera and TerraPower Isotopes is
seeking to address this supply issue and support the clinical
development of 225Ac based drugs as a potential treatment option
for cancer.
“We are excited to join forces with TerraPower
Isotopes to increase the market availability of 225Ac. While
continuing to prepare our unique technology for large-scale
production of 225Ac, as from 2024 we will also offer the
radioisotope to drug developers for their research and clinical
trials, as well as to physicians for compassionate use. This volume
would be equivalent to 50% of today’s supply and would underpin the
wider development of these targeted alpha therapy
radiopharmaceuticals as an effective treatment modality for
cancer”, commented Sven Van den Berghe, PanTera’s Chief
Executive Officer.
Scott Claunch, President of TerraPower
Isotopes, added: “Consistent with TerraPower’s vision of
developing innovative solutions to help fight disease using nuclear
science, TerraPower Isotopes is thrilled to secure this
collaboration with PanTera. Demand for 225Ac is expected to
increase as more radiopharmaceutical treatments using 225Ac are
developed to treat a variety of different types of cancers. This
collaboration will help us supply this valuable material to the
pharmaceutical industry and meet the growing global
demand.”
***
About PanTera
PanTera, an IBA and SCK CEN joint-venture, aims
to secure the large-scale production of actinium-225 (225Ac), one
of the most promising alpha-emitting radioisotopes to fight cancers
by Targeted RadioTherapy (TRT). By working towards this large-scale
production, PanTera’s ultimate goal is to improve the accessibility
of future innovative cancer therapy based on 225Ac and theranostics
in general. Learn More about PanTera on IBA booth #3023 at SNMMI
2023 Annual Meeting in Chicago, Il, USA from June 24 to June 27,
2023.
About TerraPower
TerraPower is a leading nuclear innovation
company that strives to improve the world through nuclear energy
and science. Since it was founded by Bill Gates and a group of
like-minded visionaries, TerraPower has emerged as an incubator and
developer of ideas and technologies that offer energy independence,
environmental sustainability, medical advancement and other
cutting-edge opportunities. It accepts and tackles some of the
world’s most difficult challenges. Behind each of its innovations
and programs, TerraPower actively works to bring together the
strengths and experiences of the world’s public and private sectors
to use advanced nuclear to answer pressing global needs. Learn more
at https://www.terrapower.com/.
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,800 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found
at: www.iba-worldwide.com
About SCK CEN
70 years of experience in nuclear research and
technology
SCK CEN is one of the largest research
institutions in Belgium. Every day, more than 900 employees
dedicate themselves to developing peaceful applications of
radioactivity. SCK CEN's research activities focus on three main
areas: innovative nuclear systems, nuclear waste management and
dismantling, and the resolute fight against cancer. World-renowned,
SCK CEN shares its knowledge through countless publications and
training courses, so that this pool of exceptional competence can
be maintained.
For more information, please visit
www.sckcen.be
CONTACTS
PanTera – Sven Van den Berghe–
info@Pantera-life.com
TerraPower Isotopes Press
Office – press@terrapower.com
IBA :
Soumya Chandramouli (Chief Financial Officer) –
Investorrelations@iba-group.com
Olivier Lechien – communication@iba-group.com –
+32 10 475 890
SCK CEN: Wendy De Groote –
pers@sckcen.be – +32 471 78 37 35
1 TerraPower Isotopes produced Actinium-225 is intended to be
used as starting material for further manufacturing processes and,
as starting material, is not manufactured in accordance with
current good manufacturing practices.
- 230626-PR-Pantera-TeraPower-EN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024